What Dilzem Retard Treats: Main Uses and Benefits

Dilzem Retard is applied in addressing certain symptoms across key cardiovascular domains. It generally focuses on long-term symptomatic management and is relevant in contexts involving heightened systemic burden. The prolonged-release formulation is relevant in situations where patients experience recurrent or episodic manifestations.

It is commonly used to help with managing Chronic Stable Angina and Vasospastic Angina, assisting with symptoms like chest discomfort and pressure often triggered by exertion. It is also applied in addressing persistently elevated pressure readings associated with Essential and Chronic Arterial Hypertension. Furthermore, it is relevant for managing the symptom domain of rapid, irregular heartbeat in specific supraventricular arrhythmias, such as Atrial Fibrillation or Atrial Flutter.

It provides support that may help ease the overall symptom burden, contributing to improved comfort during symptomatic periods. It is commonly used in clinical settings that involve acute or unstable symptom patterns, reflecting its role in supporting functional stability during symptomatic phases.

Quick Fact: Support for Symptoms Associated with Episodic Changes
The medication may assist with managing the speed of the heart rate, assisting with maintaining functional stability and contributing to easing the overall symptom load during episodes of heightened discomfort related to arrhythmias.

Eligibility and Contraindications

Dilzem Retard is generally prescribed for adults. Official regulatory information establishes strict rules for who must not take this medicine (contraindications) and who must use it with special caution.

Classification	Populations and Conditions
Contraindicated (Must not use)	Patients with severe heart rhythm disorders, specifically second- or third-degree AV/SA block or Sick Sinus Syndrome, unless a functioning pacemaker is present. Also includes individuals in shock, with manifest heart failure, or severe hypotension (systolic pressure < 90 mmHg). Contraindicated for those with a known hypersensitivity to diltiazem, or who are pregnant or breastfeeding.
Not Recommended	Children, as the safety and efficacy of the medication have not been established in this age group.
Use with Caution	Elderly patients and those with hepatic (liver) or renal (kidney) impairment, who require careful monitoring of their heart rate. Caution is also advised for patients with first-degree AV block, S-A block, or existing bradycardia.

This medication is also contraindicated for patients who are currently taking intravenous dantrolene or ivabradine.

Interactions with other medicines and products

The official interaction profile for diltiazem hydrochloride (Dilzem Retard) is defined by its pharmacokinetic and pharmacodynamic effects, establishing constraints on co-administration with other substances.

---

Pharmacokinetic Interactions

Diltiazem is a documented moderate inhibitor of the CYP3A4 enzyme. This mechanism increases the plasma concentration and exposure of many co-administered medicines that are CYP3A4 substrates, including certain statins (e.g., simvastatin) and immunosuppressants (e.g., ciclosporin). The concurrent use of CYP3A4 inducers (e.g., rifampicin, St. John’s Wort) is officially documented to decrease diltiazem’s own plasma concentration.

---

Pharmacodynamic Interactions and Restrictions

Co-administration with agents that affect cardiac conduction or contractility results in additive effects. This includes potentiation of risks such as pronounced bradycardia when combined with beta-blockers or cardiac glycosides (e.g., digoxin).

Regulatory restrictions formally prohibit co-administration with several medicines, including intravenous Dantrolene, oral Ivabradine, and Pimozide, due to high-risk adverse outcomes.

---

Non-Medicinal Interactions

Consumption of Grapefruit Juice is documented to potentially increase diltiazem exposure. Alcohol may also produce additive hypotensive effects.

The medication operates by functioning as an inhibitor on the L-type voltage-gated calcium channels (L-VGCCs) located across the cardiovascular system. This targeted inhibition influences three primary mechanistic domains to influence its physiological dynamics.

1. Modulating Vascular Tone and Resistance

The drug's action on L-VGCCs in the smooth muscle of blood vessel walls directly interferes with the contraction mechanism by blocking calcium influx. This results in muscle relaxation and widening (vasodilation), a change that reduces the resistance in the arterial system.

2. Influencing Heart Rate and Electrical Signaling

The drug acts on L-VGCCs in the heart's specialized electrical tissues, notably the atrioventricular (AV) node). This action slows the conduction velocity of electrical impulses, resulting in a slowing of the heart's overall rhythm and rate of impulse generation.

3. Impacting Myocardial Workload

The final domain involves the direct inhibition of L-VGCCs in the heart muscle cells. This reduces the availability of calcium required for contraction, which decreases the force of the heart's pumping action (negative inotropy). This action, in turn, results in a decrease in the workload and oxygen demand of the heart muscle.

How to Use Dilzem Retard

Dilzem Retard (diltiazem hydrochloride prolonged-release) is administered through the oral route as a core component of chronic therapy for hypertension and angina. Its usage follows standardized protocols for dosing and administration.

---

Administration Scope and Dosing

The standard frequency for this prolonged-release formulation is once daily (q.d.). The dosing schedule outlines specific starting and maintenance ranges:

Indication	Starting Dose (Adult)	Maximum Recommended Dose (Daily)
Hypertension	180 mg to 240 mg once daily	540 mg
Chronic Stable Angina	120 mg to 180 mg once daily	360 mg

Dosage adjustments, or titration, are conducted in incremental steps over intervals of 7 to 14 days to allow for the full expression of the drug's effects. If a dose is missed, the next dose is typically taken at the usual time without doubling the quantity.

---

Procedural Constraints

The prolonged-release tablet must be swallowed whole and should not be chewed, crushed, or divided. This constraint is necessary to prevent the uncontrolled release of the active ingredient. The medication may be taken without regard to food, but consistent daily timing is essential; it should be ingested at approximately the same time each day.

For older adults and patients with known hepatic or renal impairment, therapy is often initiated at a lower starting dose, such as 120 mg once daily, with subsequent increases implemented slowly and cautiously.

Research Evidence / Overview of Studies for Dilzem Retard

---

Evidence for use in Chronic Stable Angina Pectoris

Dilzem Retard was studied in research exploring chronic stable angina, a condition characterized by chest pain that often occurs during physical activity. The research primarily consisted of short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies examined outcomes related to physical discomfort and limitations, often including comparison groups receiving a placebo or other active treatments.

Researchers focused on outcomes reflecting daily functioning or activity level, such as measuring exercise duration and monitoring patient-reported outcomes describing perceived discomfort. However, there is limited information for long-term outcomes beyond the initial study periods. The evidence provides insight into short-term changes in exercise capacity, but long-term effects are not fully established, and it remains uncertain how these findings apply to long-term health markers.

---

Evidence for use in Essential Hypertension (High Blood Pressure)

Dilzem Retard was evaluated in research exploring essential hypertension, also known as high blood pressure. This evidence base largely consists of Randomized Controlled Trials (RCTs) that included comparison groups such as those receiving a placebo or other active treatments for high blood pressure. The research examined outcomes related to systemic or functional imbalance, specifically changes in systolic and diastolic blood pressure (BP) measurements.

These studies focused on tracking changes in BP readings. The findings describe patterns observed in the studies where measurements showed shifts in BP for observed groups during the short study durations. However, many of these trials focused on the surrogate marker of blood pressure reduction itself, meaning there is limited information for long-term outcomes regarding serious health events like heart attack or stroke.

---

Long-Term Studies and Durability of Follow-up

Available evidence largely comes from trials with follow-up durations that typically ranged from a few weeks up to a year. This means certainty is not established regarding the maintenance of these patterns over many years, and long-term effects are not fully established concerning continuous use.

What Is Still Uncertain About Dilzem Retard

A key area of uncertainty is the lack of extensive, long-term data tracking outcomes related to systemic or functional imbalance over several years. Additionally, evidence concerning specific, diverse subgroups, such as individuals with severe accompanying health issues, is still emerging or is limited.

Key Studies & References

1. Diltiazem - StatPearls - NCBI Bookshelf (Review on therapeutic use and special populations)

Storage and Disposal of Dilzem Retard

Dilzem Retard (diltiazem hydrochloride) must be stored in accordance with regulatory conditions to maintain stability and ensure safety. It is a mandatory requirement to keep this medication out of the reach and sight of children.

---

Storage Requirements

Official labeling specifies storage at Controlled Room Temperature, generally between 15 C and 30 C (59 F to 86 F). The product must be kept in its original container, which should be tightly closed, and stored away from excessive heat and moisture. Do not use the medicine after the expiry date printed on the packaging.

---

Disposal Instructions

Expired or unused tablets must not be disposed of via wastewater or household trash. Patients are advised to consult their pharmacist for guidance on utilizing medicine take-back programs or authorized pharmaceutical waste disposal methods.